Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14120 hypertensive patients of ASCOT-BPLA: Comparison of their relative predictability using a novel approach

Diabetic Medicine

Volumn 28, Issue 8, 2011, Pages 941-947

  Gupta, A K ^a   Prieto Merino, D ^b   Dahlof B ^c   Sever, P S ^a   Poulter, N R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes; Hypertension; Impaired fasting glucose; Metabolic syndrome; Obesity

Indexed keywords

AMLODIPINE; ATENOLOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PREDICTOR VARIABLE; RECEIVER OPERATING CHARACTERISTIC;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 79960205052     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03330.x     Document Type: Article

References (26)

1. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 1927-1935.
2. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912.
3. Reaven GM. Is diagnosing metabolic syndrome a uniquely simple way to predict incident type 2 diabetes mellitus? CMAJ 2009; 180: 601-602.
4. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 2644-2650.
5. Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagenknecht LE et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005; 112: 3713-3721.
6. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007; 167: 1068-1074.
7. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
8. Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006; 29: 1689-1696.
9. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53: 600-605.
10. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn TA, Colagiuri S, Tonkin AM et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 2008; 264: 177-186.
11. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment PanelIII, International Diabetes Federation and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30: 8-13.
12. Mukai N, Doi Y, Ninomiya T, Hata J, Yonemoto K, Iwase M et al. Impact of metabolic syndrome compared with impaired fasting glucose on the development of Type 2 diabetes in a general Japanese population. Diabetes Care 2009; 32: 2288-2293.
13. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
14. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
15. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Geneva: World Health Organization, 1999.
16. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982-988.
17. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
18. El Bassuoni EA, Ziemer DC, Kolm P, Rhee MK, Vaccarino V, Tsui CW et al. The 'metabolic syndrome' is less useful than random plasma glucose to screen for glucose intolerance. Prim Care Diabetes 2008; 2: 147-153.
19. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676-2681.
20. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009; 54: 1209-1227.
21. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150: 795-802.
22. Kolberg JA, Jørgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E et al. Development of a Type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 Cohort. Diabetes Care 2009; 32: 1207-1212.
23. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 2013-2018.
24. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725-731.
25. Meigs JB. Multiple biomarker prediction of Type 2 diabetes. Diabetes Care 2009; 32: 1346-1348.
26. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904.